Study to Investigate the Effect of the A1 Agonist Capadenoson on Ventricular HR in Patients With Persistent or Permanent Atrial Fibrillation.

Bayer28 enrolled

Overview

This trial has the primary goal to show that BAY68-4986 can lower the ventricular rate in patients with the indication persistent atrial fibrillation.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Atrial Fibrillation

Interventions

Capadenoson (BAY68-4986)DRUG

4 mg BAY68-4986 for five days

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male and/or female (without childbearing potential) white patients * History of persistent or permanent atrial fibrillation * 18 to 75 years of age Exclusion Criteria: * Patients with high-risk cardiovascular diseases * Stroke or myocardial infarction * Relevant pathological changes in the ECG or echocardiography * Medication affecting ventricular response in Afib

Locations (1)

Unnamed facility

Erfurt, Thuringia, Germany

Outcomes

Primary Outcomes

The effect of capadenoson (BAY68-4986) on rate control in patients with atrial fibrillation

Time frame: 1 week

Secondary Outcomes

To investigate safety and tolerability of this treatment with capadenoson

Time frame: 2 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.